Cat Oyler is VP of Global Public Health and Tuberculosis at Johnson and Johnson, where she previously served as Global Head of Strategy and External Innovation at Johnson & Johnson Global External Innovation. Based in Boston, Massachusetts, Cat is responsible for identifying and nurturing emerging health care related technologies in the New England area, assessing technical and business risk of the new technologies, and facilitating integration of these technologies into the Johnson & Johnson Family of Companies and their product lines. In this role, Cat works with local area faculty, researchers, entrepreneurs, and investors to identify innovative product/business opportunities that will fill strategic gaps in Johnson & Johnson’s current portfolio and will expand Johnson & Johnson’s horizons into new “white space” therapeutic areas and businesses that are strategically aligned with the future health care environment.
Cat joins Johnson & Johnson from AstraZeneca where she was responsible for evaluating and in-licensing clinical and marketed oncology products. Additionally, Cat led the business development effort for out-licensing of AstraZeneca’s oncology assets and assisted with strategic planning for oncology business development. Prior to joining AstraZeneca, Cat served in a progression of business development roles at Myriad Genetics, culminating in leading all diagnostic licensing for the Myriad Genetic Laboratories division of the company. In previous roles at Myriad, Cat worked on in- and out-licensing efforts for the pharmaceutical division, establishment of research collaborations and strategic assessment and divestment of a non-core business unit. With over ten years of BD experience and more than 15 years of biotech experience, Cat has also previously held marketing and research scientist roles at Amgen, Alza and Alkermes. Cat received a bachelor’s degree in Biology from Williams College and an MBA from the UCLA Anderson School of Management.